Preferred Label : Bivalent HPV16/18 Therapeutic Cervical Cancer Vaccine;
NCIt definition : A bivalent human papillomavirus (HPV) therapeutic vaccine containing recombinant inactivated
adenylate cyclase (CyaA) from Bordetella pertussis carrying a sequence encoding the
E7 antigen of both HPV16 and 18, with potential immunostimulatory and antiviral properties.
Upon administration of bivalent HPV16/18 therapeutic cervical cancer vaccine, the
expressed proteins may activate cell-mediated immunity and induce both cytotoxic CD8
T cells and CD4 helper T cells against the target antigens HPV16-E7 and HPV18-E7,
which leads to HPV viral clearance. Adenylate cyclase is a virulence factor of Bordetella
pertussis. Its ability to bind to CD11b-expressing dendritic cells and deliver antigens
directly to the cytosol allows the activation and induction of T-cell immunity. CyaA
may also induce a B cell response.;
Molecule name : ProCervix;
NCI Metathesaurus CUI : CL454407;
Origin ID : C112207;
UMLS CUI : C3827084;
Semantic type(s)
- concept_is_in_subset
